lilly glp 1 drug The Food and Administration has approved Foundayo, Eli Lilly's new GLP- pill to treat weight loss—the second oral weight loss drug to hit the market after Novo Nordisk's Wegovy was greenlit Comparative efficacy of tirzepatide Badge_Bestseller Quantity:Triple-Pack ($169)

lilly glp 1 drug The Food and Administration has approved Foundayo, Eli Lilly's new GLP- pill to treat weight loss—the second oral weight loss drug to hit the market after Novo Nordisk's Wegovy was greenlit Comparative efficacy of tirzepatide Badge_Bestseller Quantity:Triple-Pack ($169)

Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis | Cardiovascular Diabetology | Springer Nature Link

But recently, GLP-1s have gained mainstream attention and adoption due to their applications for weight loss—originally highlighted as a “side effect.” Those findings led to widespread media coverage and celebrity endorsements, helping fuel a rapid increase in interest and prescribing of GLP-1 medications

Badge_Bestseller

Quantity:Triple-Pack ($169)

The events manifested soon after the initiation of GLP-1 RA treatment, with a median onset time of 92 days (range: 0–3,312, n = 1,591) across all ICSRs that provided both drug initiation and AP onset times